Key Insights

Highlights

No notable highlights available yet

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 40/100

Termination Rate

0.0%

0 terminated out of 7 trials

Late-Stage Pipeline

14%

1 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

Data Visualizations

Phase Distribution

4Total
Not Applicable (1)
P 2 (2)
P 3 (1)

Trial Status

Active Not Recruiting3
Recruiting3
Withdrawn1

Clinical Trials (7)

Showing 7 of 7 trials
NCT07061977Phase 3Recruiting

Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation and Pembrolizumab Maintenance Compared to Standard Chemoradiation With Pembrolizumab Followed by Pembrolizumab Maintenance in High-Risk Cervical Cancer

NCT04580771Phase 2Active Not Recruiting

A Vaccine (PDS0101) and Chemoradiation for the Treatment of Stage IB3-IVA Cervical Cancer, the IMMUNOCERV Trial

NCT07196033RecruitingPrimary

Asian Gynecological Brachytherapy Registry in Cervical Cancer

NCT04622670Not ApplicableActive Not Recruiting

Yoga Therapy During Chemotherapy and Radiation Treatment for the Improvement of Physical and Emotional Well-Being in Patients With Stage IB2-IIIB Cervical Cancer

NCT04574635Active Not Recruiting

Human Papilloma Virus (HPV) Circulating Tumor DNA (ctDNA) in Cervical Cancer

NCT05722288Phase 2Recruiting

Time-Restricted Eating Versus Nutritional Counseling for the Reduction of Radiation or Chemoradiation Tx Side Effects in Patients With Prostate, Cervical, or Rectal Cancers

NCT05093712Withdrawn

Patient-Informed Educational Intervention for the Improvement of Cervical Cancer Literacy

Showing all 7 trials

Research Network

Activity Timeline